Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients

Table 5

Proportion and deltas of patients who achieved therapeutic goals for total cholesterol, triglycerides, and LDL-c per dose at the end of follow up compared to baseline.

Variable	Baseline n = 102 (%)				End of follow up n = 102 (%)
	Total	10/10 n = 66	20/10 n = 35	End of follow-up total	10/10		20/10
					n = 67	∆	n = 35	∆
Total cholesterol (<200 mg/dl)	47 (46.5)	30 (45.5)	17 (48.6)	96 (94.1)	65 (95.6)	−79.0 (−96.0; −39.0)	31 (88.6)	−58.0 (−131.0; −8.0)	0.001
Triglycerides (<150 mg/dl)	34 (34.3)	18 (27.7)	16 (47.1)	56 (56.0)	33 (48.5)	−56.6 (−146.0; 11.0)	23 (65.7)	−16.3 (−121.0; 9.0)	0.001
LDL-c (<100 mg/dl)	30 (34.5)	17 (29.3)	13 (44.8)	92 (91.1)	61 (89.7)	−48.8 (−88.1; −15.0)	31 (88.6)	−39.0 (−90.5; −15.8)	0.001

For the total cholesterol variable, 102 subjects were included at the end of follow up; triglycerides had data from 100 subjects for the end of follow-up; for LDL-C, data from 102 subjects were available at the end of follow-up. : baseline comparison Vs final follow up with the McNemar’s test. The valid percentage is used for the final sample size at each visit.